| |
A new personalised vaccine given in combination with a drug has stopped skin cancer returning in patients during a trial, representing a potentially watershed moment in cancer treatment.
The phase three trial involved more than 1,000 patients who had high-risk stage two, three or four…
|
Click here to view the original article.